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1. Introduction 
Crohn’s disease (CD) is one of two forms of inflammatory bowel diseases (IBD), the other 
being ulcerative colitis (UC).  CD is in fact itself a heterogeneous condition describing a 
group of closely related disease processes that result from an uncontrolled immune 
mediated inflammatory response primarily affecting the alimentary tract. CD may affect any 
part of the gastrointestinal tract and causes transmural intestinal inflammation. It is 
characterized by flares and remission. CD usually presents with diarrhea, abdominal pain 
and/or weight loss. Fever, blood in stool, oral ulcers, and/or perianal lesions may also 
occur. Most patients with CD end up requiring surgery. 
In some cases of colitis, the distinction between CD and UC cannot be clearly made despite a 
detailed evaluation based on a thorough clinical exam, endoscopy, imaging and a biopsy. 
The term “Indeterminate colitis” is used for these cases. Based on the increasing recognition 
of the so-called “indeterminate colitis” and the considerable heterogeneity even within the 
two discrete IBD subtypes, efforts calling for a revisit of IBD classification are under way.  In 
2000, the Working Party for the World Congresses of Gastroenterology, which had met in 
Vienna in1998, published their report in the journal Inflammatory Bowel Diseases and 
proposed the Vienna classification. The Vienna classification attempted to  classify CD based 
on objective variables that included age of onset, disease location, and disease behavior. The 
Vienna classification classifies CD into 24 disease clusters. Since then however, the Vienna 
classification has come under criticism due to its lack of clinical applicability, however it is 
still being used for research purposes. In 2005 Silverberg and colleagues presented the 
report of the Working Party of the Montreal World Congress of Gastroenterology in which 
they put forth the Montreal classification of IBD. Montreal classification classified CD 
largely based on variables chosen by the experts at Vienna except for adding a perianal 
disease modifier variable. Neither Vienna nor Montreal classification commented on the 
extra intestinal manifestations of  CD though.  Extra-intestinal manifestations of CD may 
include rheumatologic, dermatologic, ocular or hepatobiliary conditions. These have been 
identified in the Crohn’s Disease Activity Index (CDAI) initially introduced as far back as 
1979. 
It is estimated that approximately 750, 000 people in the United States have CD. There is a 
lot of variation in data with regard to the incidence and prevalence of CD in the US. For 
example, incidence in the US of CD is estimated at 1 to 6 per 100, 000 . The prevalence of CD 
in the US is estimated to be 10-100 per 100,000. There doesn’t seem to be a significant 
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difference in the incidence and prevalence of CD between males and females. The peak age 
of onset for CD is 15-25 years of age. There seems to be another peak between the ages of 45 
and 55. Smoking seems to predispose to CD. 
2. Etiology and pathogenesis 
The most popular theory regarding pathogenesis of CD considers it to be a result of an 
uncontrolled immune mediated inflammatory response to a still unknown trigger that 
occurs in genetically predisposed individuals, primarily affecting the alimentary tract and 
also involving the intestinal flora. 
2.1 Intraluminal factors 
Different triggers have been implicated, both external and auto-antigens. External antigens 
include viruses, bacteria and dietary agents. The most common virus implicated in the 
pathogenesis of CD is the measles virus. The most common external bacterial agent that has 
been implicated in the pathogenesis of CD is Mycobacterium paratuberculosis. An antigen 
on a dietary agent may also trigger an uncontrolled immune mediated inflammatory 
response leading to the development of CD, but no such agent has yet been identified. Auto-
antigens that have been implicated in the pathogenesis of CD may be located on non-
pathogenic bacteria which constitute the intestinal flora. Similarly it is postulated that a 
certain antigenic trigger on a yet unknown luminal agent present in the gastrointestinal tract 
may also trigger an abnormal inflammatory response within the gastrointestinal tract 
leading to intestinal inflammation. 
2.2 Epithelial barrier, innate and acquired immune actors 
Despite the lack of definitive knowledge about the potential triggering agents, it is well 
established that the main mechanism of inflammatory injury is immune mediated and 
that it occurs in genetically predisposed individuals. There are various mechanisms by 
which immune mediated injury takes place. It is a combination of the interaction between 
breakdown in the intestinal epithelial barrier, innate immune system and activation of 
acquired immune mechanisms. An important factor is abnormal or exaggerated immune 
response. HLA Class II molecules that are predominantly found on macrophages are 
considered to be the major mediators of the process of autoimmune injury. They occur in 
high numbers within the intestinal epithelial cells of patients with active CD. The HLA-
Class II molecules are responsible for antigen processing and presentation. HLA-DR 
molecules seem to play the most active role in this regard. Activated macrophages also 
secrete pro-inflammatory cytokines including IL-1, IL-6, IL-8 and TNF-alpha within the 
lamina propria of the intestinal wall. IFN- gamma is also produced and it increases 
intestinal permeability. There is decreased production of IL-2, IL-10, TNF- beta and TGF-
beta, which are down-regulatory cytokines. In patients with IBD,  this may explain 
chronic inflammation. Moreover, direct cell mediated immune mechanisms may also be 
involved in the immune pathogenesis of IBD. It is postulated that B-cell mediated 
mechanisms are also important, as there is increased secretion of IgM and IgG classes of 
antibodies by the intestinal mononuclear cells. Other immune mediators that seem to be 
involved in the pathogenesis of CD include oxygen radicals, most importantly superoxide 
molecules. Oxygen radicals are produced by activated neutrophils and they cause further 
inflammatory injury. Leukotriene Neutrophil Chemotactic Compounds (LNCC) and nitric 
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oxide also enhance the inflammatory process of IBD by causing vasodilatation and 
vascular leakage. It has been demonstrated in animal models that the inflammatory 
process of IBD is enhanced by CD-4+ T helpers. This provides evidence for a dominant 
role of T-cells in the pathogenesis of IBD. Moreover, the effectiveness of TNF-alpha and 
IFN-gamma antibodies in counteracting T-cell mediated inflammatory damage lends 
credence to the belief that both TNF-alpha and IFN-gamma are important mediators of 
the T-cell induced damage in inflammatory bowel diseases. 
2.3 Genetic predisposition 
Up to fifteen percent of patients with CD may have a first degree relative who also suffers 
from IBD. Haplotypes associated with CD are HLA-DR1/DQw5 and HLA-DRB3*0301. IBD1 
susceptibility locus on chromosome 16 is associated with CD. The NOD2 gene located on 
this locus undergoes a mutation leading to abnormality in NOD2 protein, which is an 
intracellular bacterial lipopolysaccharide receptor in monocytes. This mutation is seen in up 
to fifteen percent of patients with CD. The IBD2 susceptibility locus on chromosome 12 is 
also associated with CD. 
3. Management 
3.1 Goals 
The historic goal of treatment of CD was to induce and maintain clinical remission. 
However, it has now become evident that the natural course of disease progression of CD is 
not positively impacted if focus is laid only on clinical remission. Therefore the goal of 
treatment of CD has evolved into a broad stratagem. Current goals of medical management 
of CD include rapid induction and then maintenance of clinical as well as endoscopic 
remission. This seeks to minimize bowel damage. Other goals of management that are now 
actively pursued include decreasing rate of complications, hospitalizations, surgical 
interventions, infections, steroid use, cancer and overall mortality. Moreover, improving 
compliance and health related quality of life (HRQL) also figure prominently among current 
management goals. The goals of CD therapy continue to evolve and eventually will include 
not just minimizing the impact of the disease but perhaps obliterate it altogether. For this 
purpose, research is ongoing in search of additional biological modifiers.  Genetic studies 
are also being undertaken. 
3.2 Approach 
Traditionally, a step up approach was applied that involved starting with corticosteroids 
and evolving to more invasive and newer modalities. Then there was evidence to suggest 
that top-down therapy might be the best way to achieve the evolving goals of therapy. 
However, recently there is more support for the accelerated step-up approach. 
3.3 Supportive therapy 
In regard to diet, there is not a lot of data that suggests a strong link between diet and CD. 
However some diets that have been suggested to possibly be related to onset as well as 
increased disease activity and more severe course include diets consisting of red meats. 
Moreover, diets high in fats and refined carbohydrates also seem to be risk factors for CD 
whereas fruits and vegetables are perhaps protective. Patients are also advised to make a list 
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of others foods that seem to worsen their symptoms and to avoid consuming them. Despite 
a few studies demonstrating benefits of an elemental diet, the risk of malnutrition in 
patients on it has caused decrease in enthusiasm.  
In regard to behavioral management, regular exercise enhances functional capacity of IBD 
patients. Smoking is strongly associated with CD exacerbations. There is observational data 
to suggest that NSAID use may increase CD activity. In patients with CD, behavioral 
counseling and ways to facilitate daily living needs to be ensured.  
3.4 Advances in medical therapy 
Traditional Therapies have included systemic corticosteroids. They were and are still used 
for induction of remission in CD.  While 5-Aminosalicylates like mesalamine have 
traditionally been the primary treatment modality in mild to moderate UC but their 
effectiveness in CD has largely been marginal if any at all. Antibiotics are considered among 
the most effective and safe therapies used to treat patients with mild to moderately active 
CD.  The antibiotics most frequently used are metronidazole and ciprofloxacin. The most 
common traditional immune modulators used to maintain remission in CD  as well as UC 
are azathioprine (AZA) and 6-mercaptopurine (6-MP).The role of methotrexate (MTX) 
appears to be limited to CD.  
Newer Therapies are represented by biological immune modulators. Advances made in 
understanding the pathogenesis of CD have pushed us into the era of biological agents and 
beyond. The most important biological agents being used today are the TNF-alpha blockers. 
However, there is a long list of biologics that work by targeting other areas of the entire 
spectrum of the pathogenesis of CD. 
3.5 TNF blockers 
The first biologic agent that was approved for CD treatment was infliximab (Remicade). 
Infliximab is a half murine half human, chimeric monoclonal antibody consisting of an Fc 
portion as well as a Fab fragment which is active against TNF-alpha.  It is administered 
intravenously, usually every 8 weeks. Infliximab has been found to be effective in inducing 
and maintaining remission in moderate to severe inflammatory as well as fistulizing CD 
disease in several multicenter double-blind, placebo controlled trials. The typical induction 
regimen of infliximab is 5mg/kg intravenously at 0, 2 and 6 weeks followed by 5mg/kg 
intravenous infusion every 8 weeks.Infliximab also reduces the requirements for 
corticosteroids, leads to mucosal healing, and reduces complications such as surgical 
intervention and hospitalization. It has also demonstrated improved quality of life. Initial 
response rates to infliximab may be as high as 75% but is generally maintained in 
approximately one third of patients. 
Adalimumab (Humira) is a monoclonal IgG1 antibody against TNF-alpha which is fully 
humanized and has shown promise in the treatment of CD. Adalimumab is administered 
subcutaneously. Similar to infliximab, adalimumab works as an induction as well as a 
maintenance medication. The Classic I trial revealed that induction with 160 mg of 
adalimumab followed in two weeks by 80 mg of adalimumab  resulted in over 35 percent of 
CD patients achieving remission at 4 weeks follow up.The GAIN (Gauging Response in 
Infliximab Nonresponders) trial was conducted to evaluate response to induction by 
adalimumab of patients which also included those who had either failed to respond to 
infliximab or had developed recurrence of disease after an initial response to infliximab. It 
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was a placebo controlled double-blind trial which revealed that remission rate with 
adalimumab induction was about 21 percent, and not as good as what the Classic I trial had 
revealed. An interesting finding was that those patients who had previously either failed to 
respond to infliximab or had developed disease recurrence actually had decreased remission 
rate in response to adalimumab than the initial response to infliximab induction. The Classic 
II and CHARM trials evaluated the efficacy of maintenance with adalimumab. The CLASSIC 
II trial was a double-blind, placebo-controlled trial and went on for a year. In this trial the 
investigators maintained initial responders on 40mg of adalimumab every week or every 
other week or to placebo. After a year of this trial, 79% of the patients on 40mg every other 
week and 83% of the patients on 40mg of adalimumab every week had achieved remission 
compared to 44% of the placebo group.The CHARM trial studied 854 patients with 
moderate to severe Crohn’s disease. In CHARM, the 80/40 mg induction with adalimumab 
had already taken place. The responders to this induction regimen were then randomized to 
the two maintenance regimens of adalimumab or placebo. These patients were then 
followed for a year. Forty one percent of the patients who received adalimumab every week 
were in remission after about a year, whereas 36 percent of those who were on every other 
week of adalimumab maintenance were in remission. The CLASSIC II and CHARM trials 
also showed that adalimumab could be used as a steroid sparing agent in order to maintain 
remission in patients with CD, as most patients on adalimumab in the CLASSIC II trial were 
off steroids compared to those on placebo. In the CHARM trial, it was seen that the steroid-
free clinical remission rates were significantly higher in those patients who received 
adalimumab versus those who were on placebo. The CHARM trial also revealed a 
statistically significant decrease in hospitalization in patients who were on adalimumab 
versus placebo. Adalimumab also helped heal fistulas in patients with CD. At the end of one 
year, one third of patients who received adalimumab had achieved closure of fistula 
compared to 13 percent of those were treated with placebo. The CHARM trial was extended 
for another one year and the end of the additional year, almost 71 percent of the fistulas had 
healed in patients who received adalimumab.14 
Certolizumab pegol (Cimzia) is a humanized monoclonal agent against TNF-alpha that  is 
comprised of just the Fab fragment and does not contain the Fc moiety.  Certolizumab is 
pegylated by the addition of two polyethylene glycol molecules which increases the half-life 
as well as well its binding affinity to TNF-alpha. Certolizumab pegol is administered once a 
month subcutaneously at 400 mg dose each time. The induction regimen of Cimzia is 400mg 
subcutaneously at week 0, 2 and then 4. So far, two placebo controlled, double blind trials 
have been performed to evaluate certolizumab pegol in CD. PRECISE I (add reference) 
looked at the effectiveness of induction therapy. Even though a benefit was found in 
inducing a response with it compared to patients on placebo, the response was not 
statistically significant. The response to induction was assessed at 2 weeks, 6 weeks and then 
at 26 weeks. It was noted though that the maximum response occurred in patients who had 
CRP level higher than 10mg/dl. Patients with high CRP levels were therefore evaluated 
separately based on a previous post-hoc analysis revealing a greater rate of response in this 
patient population anyway (add reference). The primary endpoints of this study were the 
induction of clinical response at weeks 6 and a response at both weeks 6 and 26.  In this 
study, it was demonstrated that 37% of patients with CRP level higher than 10 mg/l 
experienced response at the end of 6 weeks vs. only 26% in the placebo group. The 
difference in response at weeks 2 and 26 were not statistically significant   
www.intechopen.com
 
Crohn's Disease 194 
In the PRECISE 2 trial, researchers randomized week 4 responders to certolizumab pegol 
400mg every 4 weeks to week 26 or placebo. Randomization was again stratified based on 
CRP level. It was demonstrated that 64% of the patients responded to induction therapy. 
This response was maintained in 63% of the intention to treat population up until week 26 
vs. 36% who were receiving placebo).  In terms of clinical remission at week 26, 48% of the 
patients on certolizumab pegol achieved it vs. 29% among the placebo group.   In the end, 
stratification by CRP levels did not appear to yield a significant benefit in any of these 
studies. Moreover, it was noted that the efficacy of certolizumab pegol was not impacted by 
steroid use or the use of infliximab in the past. But once again, those who had received a 
TNF blocker in the past had a lower response rate than those who had never received a 
biologic. The open-label stage of the WELCOME trial was based on CD patients who had 
been unable to tolerate infliximab or who had developed secondary loss of response to it. 
The patients received induction with  certolizumab 400 mg at weeks 0 and 2. The primary 
response defined as a decrease in CDAI of 100 was measured at week 6. It was seen that 55% 
of these patients had responded based on this criterion.  
3.6 Adhesion molecule inhibitors 
Natalizumab (Tysabri) is a monoclonal antibody against the alpha-4 subunit of integrin 
molecules which are important mediators of vascular inflammation. Integrin molecules are 
located on surface of vessels and they play an important role in adhesion and migration of 
inflammatory cells from the vasculature into inflamed tissue. Natalizumab essentially blocks 
integrin association with vascular receptors, limiting adhesion and transmigration of 
leukocytes. Specifically, in CD, natalizumab decreases inflammation by binding to alpha-4 
integrin and thus blocking adhesion and migration of inflammatory leukocytes in the gut. 
Natalizumab has not been studied in patients with UC.  Because of the incidence of PML in 
some cases and in two cases PML leading to death in MS patients who were treated with 
natalizumab, natalizumab was briefly taken off the market. In order to use natalizumab now 
in patients with CD, they must be enrolled in the Crohn’s disease Tysabri® Outreach 
Unified Commitment to Health ( CD-TOUCH™ ).Healthcare providers must also register 
with the program in order to prescribe, dispense or administer natalizumab. Treatment 
must be reauthorized every 6 months. Natalizumab is available only through infusion 
centers registered with the TOUCH™ program. Natalizumab is given in a 300 mg dose 
infused over 1 hour every 4 weeks. It is discontinued if no therapeutic benefit is observed in 
the first 12 weeks. 
Vedolizumab, previously called MLN-0002, MLN-02 or LDP-02, is similar to natalizumab 
but with some important differences. It is a recombinant humanized anti alpha-2 beta-7 
integrin monoclonal antibody, which is undergoing Phase 3 trials to test its efficacy in 
treatment of UC as well as CD. The alpha-2 beta-7 integrin subunit is relatively specific to 
the gastrointestinal tract. The Gemini I, II and III (also called the Millennium Trials) are all 
phase III clinical trials which are being conducted to test efficacy of Vedolizumab in 
inducing and maintaining remission in patient with UC and CD.  
3.7 IL-6 inhibitors 
Toclizumab is a humanized monoclonal antibody directed against the receptor of IL-6. An 
early randomized safety and efficacy trial assessing toclizumab in CD was published in 
2004. The trial had 2 treatment arms and one placebo arm with a total accrual of 36 patients. 
Even though there was a significant difference in serologic and clinical response parameters 
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between those who received toclizumab vs. placebo at assessment of the induction endpoint 
assessment, the highest response rate was two out of 10(20%) patients who received 
toclizumab. No difference was seen in terms of mucosal healing between treatment and 
placebo groups at 12 weeks.. Due to these less than encouraging results in CD, further 
clinical trials evaluating the efficacy of toclizumab in patients with IBD have not conducted 
so far. However, recently, there has been more activity in research assessing efficacy of 
toclizumab in other autoimmune diseases, most importantly rheumatoid arthritis with 
several phase II and phase III clinical trials underway. 
3.8 IFN-γ blockers 
Fontolizumab is a humanized monoclonal antibody fragment that possesses potent 
binding and neutralizing activity against human interferon-γ (IFN-γ). IFN-γ is a 
prominent pro-inflammatory effector cytokines. Two safety and clinical efficacy trials 
assessing the ability of fontolizumab in inducing remission in active CD were published 
in 2006. They did demonstrate a serologic and mucosal response in the patients who 
received fontolizumab but there was no significant difference seen in clinical remission 
between patients on fontolizumab vs. place.. In February 2010, results of a placebo 
controlled Phase 3 trial assessing efficacy of fontolizumab in patients with CD were 
published. In this trial, a total of 201 patients with Crohn's Disease Activity Index (CDAI) 
scores between 250 and 450 were randomized to receive an initial intravenous dose of 1.0 
or 4.0 mg/kg fontolizumab or placebo, followed by up to 3 subcutaneous doses of 0.1 or 
1.0 mg/kg placebo every 4 weeks. At the end of induction phase assessed at 4 weeks, 
there was no significant improvement in patients who had received fontolizumab. 
However, during the maintenance period the patient arm that received 1.0 mg/kg 
intravenous followed by 1.0 mg/kg subcutaneous of fontolizumab group had clinical 
response and significantly greater improvement in the CDAI score compared with 
patients who received placebo. But a similar improved response was not seen in the other 
fontolizumab group. However, all fontolizumab groups had significant improvement in 
C-reactive protein levels. Adverse event rates were similar in all groups. The significantly 
low levels of CRP in patients who received fontolizumab suggested a biological effect of 
fontolizumab on inflammation associated with Crohn’s. Further trials are therefore being 
planned but no trial is currently underway.  
3.9 IL-12/23p40 inhibitor 
Interleukin-12 (IL-12) and Interleukin-23 (IL-23) are functionally closely associated 
effector cytokines that seem to play an active role in promoting intestinal inflammation in 
inflammatory bowel disease. IL-12 and IL-23 are structurally separate but both exist 
linked to a common subunit p40. IL-12 attaches to the p40 subunit through its unique 
subunit p35 whereas IL-23 is attached to p40 through its unique subunit p19. Both IL-12 
and IL-23 attach to cell surface receptors on T-helper cells to trigger Th1 and Th17 
mediated inflammatory cascades respectively. Briakinumab is also a human monoclonal 
antibody directed against IL-12/23p40 subunit.. Results of a phase II dose ranging and 
efficacy study published in 2004 demonstrated a significantly higher response in patients 
on briakinumab (75%) compared to placebo (25%) at the end of 7 weeks (P=0.03). (84)A 
subsequent phase IIb randomized double blind placebo controlled clinical efficacy trial 
was started in 2007. The trial sought to test safe dose and efficacy of briakinumab in 
www.intechopen.com
 
Crohn's Disease 196 
moderate to severely active CD however it was terminated in April, 2010 without 
publication of findings. There are no other clinical trials underway testing briakinumab in 
CD or UC (Abbott ;.Dose Ranging Study Comparing the Efficacy, Safety and 
Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active 
Crohn's Disease  . In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of 
Medicine (US). 2000- [cited 2010 Oct 12]. Available from: http://clinicaltrials.gov/show/ 
NCT00562887). 
STA-5326 mesylate (also called apilimod mesylate) is a small molecule that blocks the 
release of IL-12 from peripheral blood mononuclear cells. In 2006, results of a safety and 
dose-ranging study with an accrual of 73 that evaluated oral STA-5326 mesylate (apilimod 
mesylate) in CD were published. They revealed a remission rate of between 15 and 36% at 
the end of 4 weeks. Approximately half of the patients demonstrated a decrease in mucosal 
disease activity. A subsequent phase II dose-ranging randomized placebo control clinical 
trial assessing the efficacy of oral STA-5326 mesylate (apilimod mesylate) in CD was 
undertaken between 2005 and 2008, but the results have not been published yet (B.Sands; 
Synta Pharmaceutical Corp. Study of STA-5326 Mesylate in Patients With Moderate to 
Severe Crohn's Disease In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of 
Medicine (US). 2000- [cited 2010 Oct 12]. Available from: http://clinicaltrials.gov/show/  
NCT00138840). Another similar randomized double blind placebo control  phase II study 
that sought to assess peripheral mononuclear and cytokine responses to oral STA-5326 
mesylate (apilimod mesylate) was completed in December 2008. The results of this study 
have not been published yet. There have been no additional studies evaluating STA-5326 
mesylate (apilimod mesylate) in CD since then. There are also no studies that have assessed 
STA-5326 mesylate in UC yet (P.Mannon; Synta Pharmaceutical Corp. Study of STA-5326 
Mesylate in Patients With Moderate to Severe Crohn's Disease In: ClinicalTrials.gov 
[Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2010 Oct 12]. 
Available from: http://clinicaltrials.gov/show/NCT00234741). 
Ustekinumab, a human monoclonal antibody has specific affinity to the p40 subunit. By 
doing this, ustekinumab prevents IL-12 and Il-23 from attaching to their cell surface T-
helper cell receptors and therefore helps prevent the subsequent inflammatory process. 
Results of a double blind crossover clinical study assessing efficacy of ustekinumab in 
moderate to severe CD were published in 2008. They demonstrated a statistically significant 
difference in clinical response (53%) in patients who received ustekinumab vs. those who 
were in the placebo arm (30%) (P=0.02) by the end of week 6 but this difference was not 
maintained at the end of week 8 (49% with ustekinumab vs. 40% with placebo; P=0.34). It 
was noted however that when the subgroup of previous non-responders to infliximab were 
evaluated separately, the difference in clinical response to ustekinumab vs. placebo became 
statistically significant.  Consequently, a multicenter double-blind placebo controlled 
randomized trial testing efficacy and safety of ustekinumab in subjects with moderately to 
severely active CD previously treated with TNF blockers was started. This trial is still 
ongoing with no results published so far. (Centocor Inc;. A Study of Safety and Effectiveness 
of Ustekinumab in Patients With Moderate to Severe Active Crohns Disease Who Have Been 
Previously Treated With Anti-TNF Therapy. In: ClinicalTrials.gov [Internet]. Bethesda 
(MD): National Library of Medicine (US). 2000- [cited 2010 Oct 12]. Available from: 
http://clinicaltrials.gov/show/ NCT 00771667). There are no ongoing trials testing efficacy 
of ustekinumab involving UC patients. 
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3.10 Other promising agents affecting cytokines 
Thalidomide is a glutamic acid derivative that has historically been notorious for its 
devastating teratogenic potential, a property most probably linked to it toxic effect on 
endothelial tissue structures. There is growing evidence that thalidomide in fact also 
effectively inhibits transcription of TNF among other of its functions that may also be of 
value in combating intestinal inflammation in IBD.  In a retrospective study published in 
2007, thalidomide was shown to potentially be an effective in some patients with refractory 
luminal and fistulizing Crohn’s disease. Randomized Controlled Trials testing efficacy of 
thalidomide in adults with active CD have not begun yet. It is important to note that an RCT 
conducted in children with CD, testing efficacy OF lenalidomide, an analogue of 
thalidomide  in treatment of active CD did not demonstrate any significant benefit over 
placebo (94). Similarly, despite pre-clinical evidence to support efficacy of thalidomide and 
lenalidomide in decreasing intestinal inflammation associated with IBD, no maintenance 
trials have yet been published to justify its safety for use in humans.  However, clinical trials 
are being planned. 
RDP58 is an oral d-amino acid decapeptide that has powerful immunosuppressive activity 
which includes inhibition of TNF synthesis as well inhibition of IFN-γ, IL-2 and IL-12.  It has 
been demonstrated in murine models that RDP58 is extremely effective in reducing 
intestinal inflammation including histological scores in colitis. RDP58 has also demonstrated 
variable efficacy in treatment of several inflammatory and presumably autoimmune 
conditions that include IBD,  interstitial cystitis and autoimmune encephalomyelitis. RDP58 
has demonstrated ex vivo anti-inflammatory activity in tissue from patients with CD. It has 
also demonstrated efficacy in vivo murine models. 
3.11 Mucosal barrier enhancement/restoration 
The intestinal epithelium is a part of the innate immune system of the intestinal tract. It 
functions as a protective wall that seeks to maintain a balance between the contents of the 
lumen and the immune cells and matrix that lie on the other side.  
Intestinal epithelial cells are the individual units that give rise to this normally impenetrable 
intestinal barrier by forming tight junctions. Any insult that results in the failure of the tight 
junctions to keep the contents of the two environments separate is what heralds intestinal 
inflammation by activating a hyper-reactive acquired immune system made up primarily of 
effector cells. 
Emerging therapies include therapeutic agents that seeks to enhance or restore this 
important protective immune play. Teduglitide is a dipeptidyl peptidase IV resistant 
glucagon-like peptide-2 (GLP-2) analogue. The manner in which GLP-2 repairs the intestinal 
epithelium is still unclear. However, it is being tested for its ability to restore the intestinal 
epithelial barrier. Results of a randomized, placebo-controlled, double-blind trial evaluating 
efficacy of teduglutide in inducing clinical and mucosal remission in moderate to-severe CD 
were published in 2010. They demonstrated a significant difference in clinical response and 
therefore more studies have been planned. 
Growth hormone has also demonstrated positive effects on enhancing function of 
neutrophils. Somatropin,  growth hormone, has demonstrated efficacy in repairing the 
intestinal epithelium in pre-clinical studies. Some early studies have demonstrated that 
somatropin enhances the innate immune system and repairs the intestinal epithelium 
through its positive impact on protein synthesis. A phase III study evaluating the efficacy of 
somatropin in induction of histological healing in children with Crohn's Disease (CD) was 
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completed. Publication of the results of this trial is still pending CD (L.Denson; Children's 
Hospital Medical Center, Cincinnati. Trial of Growth Hormone Therapy in Pediatric Crohn's 
DiseaseIn: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 
2000- [cited 2010 Oct 12]. Available from: http://clinicaltrials.gov/show/NCT00109473).  
Another agent that has demonstrated the ability to enhance the innate immune system is the 
synthetic growth factor Sargramostim. Sargramostim is a granulocyte-macrophage colony 
stimulating factor (GM-CSF) which specifically stimulates production of  neutrophils, 
monocytes, and epithelial cells.  A phase 1 study published in 2009 assessed efficacy of 
sargramostim in treatment of patients with moderately to severely active CD. The study 
demonstrated modest benefit with only a few patients experiencing clinical remission. There 
were no serious reported adverse drug events. 
Recently published results of a placebo-control randomized trial that assessed the efficacy of 
sargramostim in corticosteroid-dependent patients with Crohn's disease demonstrated that 
it was more effective than placebo in inducing corticosteroid-free remission. It was also 
demonstrated that treatment with sargramostim was associated with significant 
improvements in health-related quality of life. Two phase III clinical trials testing efficacy of 
sargramostim in treatment of moderate to severe CD have recently been completed but 
results have not been published yet 
(Medical Montor; Genzyme. Efficacy (Induction of Response/Remission) and Safety Study 
in Patients With Moderate to Severe Crohn's Disease  In: ClinicalTrials.gov [Internet]. 
Bethesda (MD): National Library of Medicine (US). 2000- [cited 2010 Oct 12]. Available from: 
http://clinicaltrials.gov/show/NCT00206674) (Medical Monitor; Genzyme.Study in 
Patients With Crohn's Disease Who Are Steroid Dependent, Despite Previous Unsuccessful 
Attempts to Reduce Steroids Due to Worsening of Crohn's Disease In: ClinicalTrials.gov 
[Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2010 Oct 12]. 
Available from: http://clinicaltrials.gov/show/NCT00206596). 
There is evidence for granulocyte colony-stimulating factor’s (G-CSF) ability to inhibit 
effects of T helper 1 cells and of its ability to induce IL-10-secreting regulatory T cells. 
Filgrastim, a synthetic granulocyte colony-stimulating factor (G-CSF) that specifically 
stimulates production of neutrophils has also shown promise in early safety and efficacy 
trials.  In a recently published early phase study, the clinical benefit of G-CSF therapy in 
active CD was tested.  The results of the study were important as it was demonstrated that 
clinical benefit from G-CSF treatment was associated with induction of IL-10 secreting T 
cells as well as a rise in plasmacytoid dendritic cells in the lamina propria of the inflamed 
intestinal mucosa. Another phase I study assessing the efficacy of G-CSF in inducing an 
immune and clinical response in CD patients was recently completed but the results of this 
trial have not been published yet National Institute of Allergy and Infectious Diseases;  
National Institutes of Health Clinical Center. G-CSF to Treat Crohn's Disease In: 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 
2010 Oct 12]. Available from: http://clinicaltrials.gov/show/NCT00025805). 
3.12 Intra-luminal targets 
While there is no paucity of hypotheses regarding implication of intra-luminal agents as 
triggers of inflammation, the real advance in devising therapeutic strategies by modulating 
intra-luminal agents has been the realization that intestinal inflammation seen in CD is 
actually a result of an imbalance between the intestinal milieu comprising of micobiota, 
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most likely gut commensals on one side and various components of the immune system on 
the other. This theory receives more credence with the observation of increased 
inflammation seen in murine models with defects in any of these components. 
Based on the sometimes contradictory observations made, it is very plausible that there are 
indeed competing and opposing effects of microorganisms in the gut. This dilemma is 
explained well when one notes that intestinal inflammation is not just the net result of the 
imbalance between intra-luminal antigens and intestinal immune actors but in fact is also 
related to the imbalance between the so considered commensal and pathogenic strain of 
bacteria residing within the intestinal lumens. 
Another group of intraluminal actors that has recently garnered the interest of researchers 
comprises the parasitic helminths.  It has been postulated that as development and 
industrialization became harbingers of improved hygiene, intestinal colonization of people 
with helminths, a fact of life across the entire globe just a hundred years ago, began to 
subside.  Additionally, it was noted that almost precisely around the same period,  there 
began to occur a substantial increase in the  incidence of autoimmune conditions such as 
inflammatory bowel disease among populations residing in these rapidly industrializing 
nations. The association between the two phenomena became clearer when evidence of the 
role of helminths in depressing the intestinal immune reaction also began to emerge. It is 
now being seen that there seems to be a rapidly rising rate of inflammatory bowel disease 
among the urbanized populations of several rapidly developing countries whereas their 
rural counterparts continue to largely enjoy protection from this process. Another theory 
brought to the fore is popularly termed as the "IBD hygiene hypothesis".  It theorizes that 
immune deregulation occurs early in childhood among populations that are brought up in 
extremely hygienic environments largely devoid of helminthic colonization. It has been 
postulated that intestinal helminthic colonizers may actually enhance one’s immune 
regulation processes. Through this mechanism, they may prove to be effective weapons 
against the various effector cells that are the greatest drivers of  the inflammatory cascade 
representative of CD.  
There is also evidence based on murine models suggesting that helminths have a protective 
effect against the development of colitis.  There is evidence based on an open-label clinical 
trial done on patients with CD that supports the therapeutic role of helminths in these 
patients.  These studies used live ova from porcine whipworm as an oral therapeutic 
intervention.  
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